HC Wainwright Predicts Stronger Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Legend Biotech in a research report issued on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.18) per share for the quarter, up from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.07) EPS.

A number of other brokerages have also recently commented on LEGN. Piper Sandler restated an “overweight” rating and set a $78.00 price target on shares of Legend Biotech in a research note on Monday, December 30th. Guggenheim reiterated a “neutral” rating on shares of Legend Biotech in a research note on Wednesday, March 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. Morgan Stanley lowered their target price on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $83.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Legend Biotech Stock Performance

Shares of LEGN stock opened at $37.94 on Monday. The stock has a market capitalization of $6.93 billion, a P/E ratio of -39.94 and a beta of 0.19. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The firm’s 50 day moving average is $35.75 and its 200 day moving average is $40.61. Legend Biotech has a 12 month low of $30.17 and a 12 month high of $65.45.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.46. The company had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. Legend Biotech’s revenue was up 134.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.40) EPS.

Institutional Trading of Legend Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Lansforsakringar Fondforvaltning AB publ bought a new position in shares of Legend Biotech during the 4th quarter valued at $914,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Legend Biotech during the 4th quarter valued at $776,000. Polar Asset Management Partners Inc. grew its holdings in shares of Legend Biotech by 65.8% during the 4th quarter. Polar Asset Management Partners Inc. now owns 24,638 shares of the company’s stock valued at $802,000 after purchasing an additional 9,779 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Legend Biotech during the 4th quarter valued at $56,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Legend Biotech by 36.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,438 shares of the company’s stock valued at $4,440,000 after purchasing an additional 36,181 shares during the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).